SL Science
SLBT
1.51
0.00
0.00%
SL Science
US · SLBT
#3370 by market cap
Listed 2025
1.51
0.00
0.00%
Live - 5344 symbols - heartbeat 219s ago
· 2026-10-08 09:31
Pre-market
1.51
0.00%
After-hours
1.50
-0.66%
Overnight
1.51
0.00%
- Market cap
- 846.75M
- P/E (TTM)i
- -137.27
- P/Bi
- 94.38
- EPSi
- -0.01
- Div yieldi
- 0.00%
- 52W posi
- 1%
Reader sentiment
Are you bullish or bearish on SLBT?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 946.66, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 3 years
Latest year -34.68% YoY
Margins
- Gross margin
- 35.27%
- Operating margin
- -174.65%
- Net margin
- -173.85%
Key ratios & quality
- Altman Z-Scorei
- 946.66
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 878.97K | 3.36M | 2.20M |
| Gross profit | 738.01K | 1.93M | 775.06K |
| Selling & admin expenses | 641.18K | 1.11M | 2.54M |
| Research & development | 0 | 2.02M | 2.07M |
| Operating profit | 96.83K | -1.20M | -3.84M |
| Pretax profit | 532.87K | -1.13M | -3.82M |
| Tax | 133.84K | 57.64K | -4 |
| Net profit | 399.04K | -1.19M | -3.82M |
| Basic EPS | 0 | 0 | 0 |
| Diluted EPS | 0.00 | 0.00 | -0.01 |
| Line item | 2024-12 | 2025-06 | 2025-12 |
|---|---|---|---|
| Revenue | -- | -- | -- |
| Gross profit | -- | -- | -- |
| Selling & admin expenses | -- | -- | -- |
| Research & development | -- | -- | -- |
| Operating profit | -- | -- | -- |
| Pretax profit | -- | -- | -- |
| Tax | -- | -- | -- |
| Net profit | -- | -- | -- |
| Basic EPS | -- | -- | -- |
| Diluted EPS | -- | -- | -- |
Balance sheet
| Line item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total current assets | 3.49M | 5.86M | 1.43M |
| Cash & ST investments | 276.85K | 3.68M | 1.26M |
| Inventory | 1.48M | 1.36M | 0 |
| Total assets | 4.24M | 5.93M | 2.82M |
| Total current liabilities | 183.03K | 69.20K | 468.54K |
| Short-term debt | 149.59K | -- | 148.66K |
| Long-term debt | -- | -- | -- |
| Total liabilities | 668,066.00 | 204,899.00 | 533,277.00 |
| Total equity | 3.57M | 5.73M | 2.28M |
| Retained earnings | 0 | -1.66M | -5.48M |
| Line item | 2024-12 | 2025-06 | 2025-12 |
|---|---|---|---|
| Total current assets | 5.86M | 4.46M | 1.43M |
| Cash & ST investments | 3.68M | 3.37M | 1.26M |
| Inventory | 1.36M | 722.76K | 0 |
| Total assets | 5.93M | 5.79M | 2.82M |
| Total current liabilities | 69.20K | 910.36K | 468.54K |
| Short-term debt | -- | 154.92K | 148.66K |
| Long-term debt | -- | -- | -- |
| Total liabilities | 204,899.00 | 1,061,102.00 | 533,277.00 |
| Total equity | 5.73M | 4.73M | 2.28M |
| Retained earnings | -1.66M | -3.27M | -5.48M |
Cash flow
| Line item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating cash flow | -2.45M | 280.16K | -1.91M |
| Depreciation & amortization | 37.19K | 47.25K | 93.69K |
| Free cash flow | -2.64M | 272.19K | -2.23M |
| Dividends paid | -- | -- | -- |
| Stock buybacks / issuance | 0 | 7.24M | 0 |
| Ending cash balance | 439.35K | 4.14M | 1.26M |
| Line item | 2024-12 | 2025-06 | 2025-12 |
|---|---|---|---|
| Operating cash flow | -- | -- | -- |
| Depreciation & amortization | -- | -- | -- |
| Free cash flow | -- | -- | -- |
| Dividends paid | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- |
| Ending cash balance | -- | -- | -- |
Returns & efficiency
| Line item | 2023 | 2024 | 2025 |
|---|---|---|---|
| ROE %i | 11.17 | -25.62 | -95.36 |
| ROA %i | 9.41 | -23.42 | -87.32 |
| ROIC %i | 9.65 | -25.31 | -92.20 |
| 5-year avg ROE %i | -- | -- | -- |
| EBIT margin %i | 11.02 | -35.56 | -174.65 |
| FCF / sales %i | -- | 8.09 | -- |
| Current ratioi | 19.09 | 84.61 | 3.05 |
| Quick ratioi | 2.16 | 57.01 | 2.96 |
| Debt / assetsi | 12.97 | 0.00 | 7.58 |
| LT debt / equityi | 11.21 | -- | 2.83 |
| Interest coveragei | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- |
| Line item | 2024-12 | 2025-06 | 2025-12 |
|---|---|---|---|
| ROE %i | -25.62 | -50.09 | -95.36 |
| ROA %i | -23.42 | -40.91 | -87.32 |
| ROIC %i | -25.31 | -48.18 | -92.20 |
| 5-year avg ROE %i | -- | -- | -- |
| EBIT margin %i | -35.56 | -70.65 | -174.65 |
| FCF / sales %i | 8.09 | -- | -- |
| Current ratioi | 84.61 | 4.90 | 3.05 |
| Quick ratioi | 57.01 | 3.84 | 2.96 |
| Debt / assetsi | 0.00 | 5.28 | 7.58 |
| LT debt / equityi | -- | 3.19 | 2.83 |
| Interest coveragei | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- |
Revenue breakdown most recent period
Business
Exosome Products100.00%
Region
Taiwan100.00%
Quote time 2026-10-08 09:31:03 · For reference only, not investment advice and not tailored to your situation.